2019 American Transplant Congress
Anti-Complement Component 5 Antibody Based Immunosuppression Induced Accommodation in ABO Incompatible Heart Transplantation
*Purpose: Plasmapheresis in combination with immunoglobulin and rituximab is often used to induce accommodation in ABO-incompatible (ABOi) living-donor transplantation; however, this regimen cannot be applied…2019 American Transplant Congress
Racial Disparities in Documentation of Non-Adherence and Its Relation to Rejection in Pediatric Kidney Transplant Recipients
*Purpose: Black patients have historically been disadvantaged throughout the transplant process. Many factors impact the success of kidney transplantation, but the need for strict adherence…2019 American Transplant Congress
Assessing the Effectiveness of Early Maintenance Immunosuppression Practices in Liver Transplantation
University of Pennsylvania, Philadelphia, PA
*Purpose: Evidence regarding the efficacy of maintenance immunosuppression (IS) regimens for liver transplantation (LT) arise from clinical trials. However, the ‘real world’ effectiveness of such…2019 American Transplant Congress
Prevalence of Non-Adherence to Immunosuppressive Medications in Kidney Transplant Recipients, Barriers and Predictors
*Purpose: Non-adherence to immunosuppressant therapy (IST) is one of the major factors leading to graft rejection. To our knowledge, limited data exist on the prevalence…2019 American Transplant Congress
Impact Of Selective Cd28 Blockade On Protective Immunity To A Murine Epstein-Barr Virus Homolog
Surgery, Emory University, ATLANTA, GA
*Purpose: CTLA-4Ig blocks CD80/CD86, the ligands for both CD28 and CTLA-4. Thus, in addition to the intended effect of blocking CD28-mediated costimulation, CTLA4-Ig also has…2019 American Transplant Congress
Infectious Complications in Tocilizumab-Treated Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Tocilizumab blocks IL-6 signaling, inhibiting maturation of B cells to plasma cells and antibody production. We have used tocilizumab since 2012 to treat kidney…2019 American Transplant Congress
Development of a Pharmacy Collaborative Practice Agreement to Improve Efficiency and Management of Prescribing in a Renal Transplant Clinic
*Purpose: This study describes the development of a Collaborative Pharmacy Practice Agreement (CPPA) between transplant pharmacists and physicians and assesses change in prescription volume and…2019 American Transplant Congress
The Effect Of Tacrolimus Trough Variability On Kidney Transplant Outcomes
*Purpose: High variability in tacrolimus as assessed by tacrolimus coefficient of variability (TCV) in trough levels of kidney transplant recipients (KTRs) has been associated with…2019 American Transplant Congress
Conversion to Belatacept in Kidney Transplant Recipients with Systemic Lupus Erythematosus
Columbia University MC, New York, NY
*Purpose: Lupus nephritis (LN) results in the need for renal replacement therapy (RRT) in 10-30% of LN pts and 30% receive a kidney transplant (KT).…2019 American Transplant Congress
Patient Reported Side Effects Associated with Reduced Quality of Life after Living Donor Kidney Transplant
Northwestern University, Chicago, IL
*Purpose: As living donor kidney transplant (LDKT) graft and patient survival approaches 100%, the focus of care turns to patient reported outcome measures such as…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 138
- Next Page »